Tag: Zepbound and Mounjaro revenue

Eli Lilly’s (NYSE: LLY) stock took a steep dive, falling nearly 10% in premarket trading following a Q3 earnings report that failed to meet Wall Street’s revenue expectations. The company, known for its leadership in innovative drugs, including weight-loss and diabetes medications, also reduced its profit guidance and lowered the high end of its annual…